A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

B. Melichar; S. Bracarda; V. Matveev; B. Alekseev; S. Ivanov; A. Zyryanov; R. Janciauskiene; E. Fernebro; P. Mulders; S. Osborne; S. Jethwa; G. Mickisch; M. Gore; R.J.A. van Moorselaar; M. Staehler; N. Magne; J. Bellmunt

doi:10.1093/annonc/mdt228

A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

B. Melichar, S. Bracarda, V. Matveev, B. Alekseev, S. Ivanov, A. Zyryanov, R. Janciauskiene, E. Fernebro, P. Mulders, S. Osborne, S. Jethwa, G. Mickisch, M. Gore, R.J.A. van Moorselaar, M. Staehler, N. Magne, J. Bellmunt

Urology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	2396-2402
Journal	Annals of Oncology
Volume	24
Issue number	9
DOIs	https://doi.org/10.1093/annonc/mdt228
Publication status	Published - 2013

Access to Document

10.1093/annonc/mdt228

Cite this

Melichar, B., Bracarda, S., Matveev, V., Alekseev, B., Ivanov, S., Zyryanov, A., ... Bellmunt, J. (2013). A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Annals of Oncology, 24(9), 2396-2402. https://doi.org/10.1093/annonc/mdt228

Melichar, B. ; Bracarda, S. ; Matveev, V. ; Alekseev, B. ; Ivanov, S. ; Zyryanov, A. ; Janciauskiene, R. ; Fernebro, E. ; Mulders, P. ; Osborne, S. ; Jethwa, S. ; Mickisch, G. ; Gore, M. ; van Moorselaar, R.J.A. ; Staehler, M. ; Magne, N. ; Bellmunt, J. / A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. In: Annals of Oncology. 2013 ; Vol. 24, No. 9. pp. 2396-2402.

@article{a08c82d1efd5404aa18b503b298b5b6c,

title = "A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN",

author = "B. Melichar and S. Bracarda and V. Matveev and B. Alekseev and S. Ivanov and A. Zyryanov and R. Janciauskiene and E. Fernebro and P. Mulders and S. Osborne and S. Jethwa and G. Mickisch and M. Gore and {van Moorselaar}, R.J.A. and M. Staehler and N. Magne and J. Bellmunt",

year = "2013",

doi = "10.1093/annonc/mdt228",

language = "Undefined/Unknown",

volume = "24",

pages = "2396--2402",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "9",

}

Melichar, B, Bracarda, S, Matveev, V, Alekseev, B, Ivanov, S, Zyryanov, A, Janciauskiene, R, Fernebro, E, Mulders, P, Osborne, S, Jethwa, S, Mickisch, G, Gore, M, van Moorselaar, RJA, Staehler, M, Magne, N & Bellmunt, J 2013, 'A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN', Annals of Oncology, vol. 24, no. 9, pp. 2396-2402. https://doi.org/10.1093/annonc/mdt228

A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. / Melichar, B.; Bracarda, S.; Matveev, V.; Alekseev, B.; Ivanov, S.; Zyryanov, A.; Janciauskiene, R.; Fernebro, E.; Mulders, P.; Osborne, S.; Jethwa, S.; Mickisch, G.; Gore, M.; van Moorselaar, R.J.A.; Staehler, M.; Magne, N.; Bellmunt, J.

In: Annals of Oncology, Vol. 24, No. 9, 2013, p. 2396-2402.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

AU - Melichar, B.

AU - Bracarda, S.

AU - Matveev, V.

AU - Alekseev, B.

AU - Ivanov, S.

AU - Zyryanov, A.

AU - Janciauskiene, R.

AU - Fernebro, E.

AU - Mulders, P.

AU - Osborne, S.

AU - Jethwa, S.

AU - Mickisch, G.

AU - Gore, M.

AU - van Moorselaar, R.J.A.

AU - Staehler, M.

AU - Magne, N.

AU - Bellmunt, J.

PY - 2013

Y1 - 2013

U2 - 10.1093/annonc/mdt228

DO - 10.1093/annonc/mdt228

M3 - Article

C2 - 23803225

VL - 24

SP - 2396

EP - 2402

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -